Overview

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment

Status:
Not yet recruiting

Trial end date:
2027-02-01

Target enrollment:

Participant gender:

Summary

ERASE is part of the MyeloMATCH initiative, Young Adult Basket and is a Tier 2 study. The study is comparing the use of Cytarabine to Cytarabine and Venetoclax, Daunorubicin/Cytarabine Liposome and Venetoclax, and Azacitidine and Venetoclax.

Phase:

Phase 2

Details

Lead Sponsor:

Eastern Cooperative Oncology Group

Collaborator:

National Cancer Institute (NCI)

Treatments:

Azacitidine
Cytarabine
Daunorubicin
Venetoclax